Insight journal, Insight journal - Company

Bavarian Nordic: Biotechnology partnering activity 2009-2014

Posted on 11 August 2014

Tags: , , ,

Bavarian Nordic is an international biotechnology headquartered in Denmark. The company focuses its efforts on cancer and infectious diseases. Bavarian Nordic is specialized in vaccines based on viral vectors. The company’s partnering, collaborative R&D and licensing activity are reviewed here.

A fully integrated company, Bavarian Nordic specializes in viral vector vaccines for infectious diseases. It has multiple candidates in its pipeline targeted towards immunotherapy.

Since 2009 Bavarian Nordic Pharmaceuticals announced 12 partnering / licensing deals.

Abstracted from: Partnering Agreements with Bavarian Nordic 2009-2014

Bavarian Nordic, unlike other big biotech companies has not entered into many partnering deals since 2009. However, 2011 saw a peak in partnering activity with the marketing of Imavamune, a smallpox vaccine.

The following figure shows the level of Bavarian Nordic partnering deal announcements since 2009.

Figure 1: Bavarian Nordic partnering deals 2009-2014

Figure 1: Bavarian Nordic partnering deals 2009-2014

Figure 1: Bavarian Nordic partnering deals 2009-2014

Source: Current Agreements, 2014

Bavarian Nordic has released products to treat late stage prostate cancer and smallpox. It continues to in-license technologies to build its expertise in viral vectors for treating infectious diseases and to broaden platform applicability.

The following table provides an overview of the partnering deals announced by Bavarian Nordic Pharmaceuticals based on therapy area disclosed. Our report provides a more detailed insight into the precise therapeutic target of each deal. See: Partnering Agreements with Bavarian Nordic 2009-2014

Figure 2: Bavarian Nordic partnering deals by therapy area 2009-2014

Figure 2: Bavarian Nordic partnering deals by therapy area 2009-2014

Figure 2: Bavarian Nordic partnering deals by therapy area 2009-2014

Source: Current Agreements, 2014

Further analysis of these deals shows that Bavarian Nordic has a preference for supply and contract service deals. Several governmental agencies such as the Department of Defense and National Institute of Allergy and Infectious Diseases sign contract service deals with Bavarian Nordic for the development of vaccine to combat infectious diseases. Our report Partnering Agreements with Bavarian Nordic 2009-2014 provides a better understanding of the deals captured.

The following table provides an overview of the partnering deals announced by Bavarian Nordic based on deal type disclosed.

Figure 3: Bavarian Nordic partnering deals by deal type 2009-2014

 

Figure 3: Bavarian Nordic partnering deals by deal type 2009-2014

Figure 3: Bavarian Nordic partnering deals by deal type 2009-2014

Source: Current Agreements, 2014

When looking at stage of development at partnering deal signing, the most popular stages at signing are marketed stage deals.

The following table provides an overview of the partnering deals announced by Bavarian Nordic Pharmaceuticals based on stage of development at signature.

Figure 4: Bavarian Nordic partnering by stage of development 2009-2014

Figure 4: Bavarian Nordic partnering by stage of development 2009-2014

Figure 4: Bavarian Nordic partnering by stage of development 2009-2014

 

Source: Current Agreements, 2014

Bavarian Nordic has signed around 12 partnering, collaborative R&D and licensing deals since 2009. The following provides a summary of the top deals by headline value.

Figure 5: Top Bavarian Nordic partnering deals by headline value 2009-2014

Figure 5: Top Bavarian Nordic partnering deals by headline value 2009-2014

Figure 5: Top Bavarian Nordic partnering deals by headline value 2009-2014

 

Source: Current Agreements, 2014

Our report provides more detailed insight into the details of each deal. See: Partnering Agreements with Bavarian Nordic 2009-2014

Bavarian Nordic partnering at Current Agreements

View all partnering deals for Bavarian Nordic:  2014 | 2013 | 2012 | 2011 | 2010 | 2009

Full details on each deal can be found at CurrentAgreements (subscription required)

Or purchase report: Partnering Agreements with Bavarian Nordic 2009-2014

More   

Summary profile data for Bavarian Nordic

Partnering interests for Bavarian Nordic

M&A activity for Bavarian Nordic                     

 

Available reports from Current Partnering

Report: Partnering Agreements with Bavarian Nordic 2009-2014 

Report: Partnering Deals and Alliances with Big Biotech

Available resources for deal coverage for Bavarian Nordic

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Read: more on Bavarian Nordic company profile, recent partnering, M&A and financing news and articles

 

Related

Report: Finding Biopharma Licensing and Collaboration Partners

View: Current Partnering Insight Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering Insight M&A Scorecard – view top life science M&A deals by value

View: Current Partnering Insight Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering Insight Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Insight Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Insight Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk

View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter                                                                                   

Print Friendly, PDF & Email

Leave a Reply